MX364495B - Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos. - Google Patents
Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos.Info
- Publication number
- MX364495B MX364495B MX2014007103A MX2014007103A MX364495B MX 364495 B MX364495 B MX 364495B MX 2014007103 A MX2014007103 A MX 2014007103A MX 2014007103 A MX2014007103 A MX 2014007103A MX 364495 B MX364495 B MX 364495B
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- nucleic acid
- eye disease
- related eye
- treating nucleic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Eyeglasses (AREA)
Abstract
La presente invención se refiere a una composición para usarse en el tratamiento de una enfermedad ocular relacionada con ácido nucleico, en donde la composición comprende una nucleasa y un excipiente, oftálmico; en donde la nucleasa es seleccionada del grupo consistente de Desoxirribonucleasa I (ADNasa I), Desoxirribonucleasa II (ADNasa II) , Desoxirribonucleasa III (ADNasa III), nucleasa micrococal y una ADNasa recombinante; y en donde la enfermedad ocular relacionada con ácido nucleico es seleccionada del grupo que consiste de la enfermedad de ojo seco, queratitis, laminar, queratitis asociada con lente de contacto, endoftalmitis, querotapatía cristalina infecciosa, pénfigo de cicatrización ocular (OCP), queratoconjuntivitis seca (Kcs), síndrome de Sjögren, queratoconjuntivitis seca asocaiada con síndrome de no Sjögren, queratitis seca, síndrome seco, xeroftalmia, trastorno de película lagrimal, producción disminuida de lágrimas, difidencia lagrimal acuosa (ATD), una infección bacteriana ocular y disfunción de la glándula de Meibomio (MGD).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161569604P | 2011-12-12 | 2011-12-12 | |
US201261600377P | 2012-02-17 | 2012-02-17 | |
PCT/US2012/051562 WO2013089835A1 (en) | 2011-12-12 | 2012-08-20 | Composition and method for treating nucleic acid-related eye disease |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014007103A MX2014007103A (es) | 2015-05-11 |
MX364495B true MX364495B (es) | 2019-04-29 |
Family
ID=48613071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014007103A MX364495B (es) | 2011-12-12 | 2012-08-20 | Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos. |
Country Status (15)
Country | Link |
---|---|
US (3) | US9867871B2 (es) |
EP (1) | EP2790722B1 (es) |
JP (1) | JP6202400B2 (es) |
KR (1) | KR101898438B1 (es) |
CN (1) | CN104220087A (es) |
AU (1) | AU2012352983B2 (es) |
BR (1) | BR112014014378A2 (es) |
CA (1) | CA2858983C (es) |
DK (1) | DK2790722T3 (es) |
ES (1) | ES2713519T3 (es) |
IL (1) | IL232999B (es) |
MX (1) | MX364495B (es) |
RU (1) | RU2642609C2 (es) |
WO (1) | WO2013089835A1 (es) |
ZA (1) | ZA201404320B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013169382A1 (en) * | 2012-05-07 | 2013-11-14 | DePuy Synthes Products, LLC | Methods and devices for treating intervertebral disc disease |
US9919034B2 (en) | 2014-03-28 | 2018-03-20 | Tamir Biotechnology, Inc. | Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V |
US10835598B2 (en) | 2014-08-18 | 2020-11-17 | Orgenesis Inc. | Prophylactic protection against viral infections, particularly HIV |
EP3307238A1 (en) * | 2015-06-15 | 2018-04-18 | Tamir Biotechnology, Inc. | Pharmaceuticals for treatment of viral infections of the eye |
EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
WO2019005222A1 (en) * | 2017-06-29 | 2019-01-03 | Advaite LLC. | TREATMENT AND DIAGNOSIS OF OCULAR SURFACE DISORDERS |
AU2018318313A1 (en) | 2017-08-18 | 2020-03-19 | Neutrolis Inc.. | Engineered DNase enzymes and use in therapy |
WO2019065936A1 (ja) * | 2017-09-29 | 2019-04-04 | 参天製薬株式会社 | 涙液中のmuc5ac量の測定方法 |
WO2019231853A1 (en) | 2018-06-01 | 2019-12-05 | Aurora Tears Technology, Inc. | Systems and methods for generating and applying biomimicry tear films |
US11253395B2 (en) * | 2018-06-01 | 2022-02-22 | Aurora Tears Technology, Inc. | Systems and methods for generating and applying biomimicry tear films |
US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
KR20210072790A (ko) | 2018-10-08 | 2021-06-17 | 뉴트롤리스 인코포레이티드 | 제조 및 치료를 위한 dnase 효소의 엔지니어링 |
US11058724B2 (en) | 2018-10-08 | 2021-07-13 | Neutrolis, Inc. | Methods of using DNASE1-like 3 in therapy |
US11352613B2 (en) | 2019-02-04 | 2022-06-07 | Neutrolis, Inc. | Engineered human extracellular DNASE enzymes |
RU2740363C1 (ru) * | 2020-08-03 | 2021-01-13 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ оценки эффективности лечения синдрома сухого глаза у больных сахарным диабетом |
BE1028712B1 (fr) | 2020-10-16 | 2022-05-18 | Onelife S A | Composition para-pharmaceutique ou pharmaceutique administrable à un être vivant, de préférence un être humain comprenant au moins une enzyme pour le traitement et/ou la prévention d'infections bactériennes impliquant la formation de biofilm |
CN115595315A (zh) * | 2021-06-28 | 2023-01-13 | 四川大学华西医院(Cn) | 核糖核酸酶i在抑制疼痛的药物中的新用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1575359A1 (ru) | 1988-06-14 | 1991-05-15 | Институт Морфологии Человека Амн Ссср | Способ получени рибонуклеотидов |
AU8502298A (en) | 1997-07-29 | 1999-02-22 | John Erlandson | Pencils containing reclaimed rubber |
GB9716376D0 (en) * | 1997-08-01 | 1997-10-08 | Isis Innovation | Artificial tear formulation |
US6759040B1 (en) * | 1997-09-12 | 2004-07-06 | University Of Maryland, College Park | Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures |
US20080096817A1 (en) | 1998-07-30 | 2008-04-24 | Regenerx Biopharmaceuticals, Inc. | METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES |
AU3664102A (en) * | 2000-12-01 | 2002-06-11 | Battelle Memorial Institute | Method for stabilizing biomolecules in liquid formulations |
EP1383529A4 (en) * | 2001-03-15 | 2005-06-29 | Regenerx Biopharmaceuticals | METHOD FOR THE TREATMENT OF EYES AND SQUATING TISSUES WITH THYMOSINE 4 (T 4), ANALOGUE, ISOFORMS AND OTHER DERIVATIVES |
US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
US20050089546A1 (en) * | 2003-09-16 | 2005-04-28 | Dick Wurtman | Compositions and methods comprising complex carbohydrate and alpha-lactalbumin |
EP1753445A4 (en) * | 2004-05-06 | 2009-05-20 | Molichem Medicines Inc | TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS |
EP1848541A4 (en) * | 2005-02-07 | 2013-01-16 | Pharmalight Inc | METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS |
US20080139545A1 (en) * | 2006-05-22 | 2008-06-12 | Won-Taek Choe | Formulation to treat ear infection |
US8753662B2 (en) * | 2007-02-15 | 2014-06-17 | National Jewish Health | Methods and compositions for the disruption of biofilms |
WO2009002790A2 (en) * | 2007-06-26 | 2008-12-31 | Bausch & Lomb Incorporated | Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
TW200927192A (en) * | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
GB2477914B (en) * | 2010-02-12 | 2012-01-04 | Univ Newcastle | Compounds and methods for biofilm disruption and prevention |
-
2012
- 2012-08-20 RU RU2014128564A patent/RU2642609C2/ru active
- 2012-08-20 ES ES12858050T patent/ES2713519T3/es active Active
- 2012-08-20 MX MX2014007103A patent/MX364495B/es active IP Right Grant
- 2012-08-20 KR KR1020147019155A patent/KR101898438B1/ko active IP Right Grant
- 2012-08-20 DK DK12858050.3T patent/DK2790722T3/en active
- 2012-08-20 AU AU2012352983A patent/AU2012352983B2/en active Active
- 2012-08-20 BR BR112014014378A patent/BR112014014378A2/pt not_active Application Discontinuation
- 2012-08-20 CA CA2858983A patent/CA2858983C/en active Active
- 2012-08-20 WO PCT/US2012/051562 patent/WO2013089835A1/en active Application Filing
- 2012-08-20 CN CN201280069247.8A patent/CN104220087A/zh active Pending
- 2012-08-20 EP EP12858050.3A patent/EP2790722B1/en active Active
- 2012-08-20 US US14/362,589 patent/US9867871B2/en active Active
- 2012-08-20 JP JP2014547214A patent/JP6202400B2/ja active Active
-
2014
- 2014-06-08 IL IL232999A patent/IL232999B/en active IP Right Grant
- 2014-06-11 ZA ZA2014/04320A patent/ZA201404320B/en unknown
-
2017
- 2017-01-03 US US15/397,595 patent/US10328129B2/en active Active
-
2019
- 2019-06-17 US US16/442,739 patent/US11376312B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9867871B2 (en) | 2018-01-16 |
EP2790722A4 (en) | 2015-09-09 |
CA2858983A1 (en) | 2013-06-20 |
ZA201404320B (en) | 2015-11-25 |
US11376312B2 (en) | 2022-07-05 |
BR112014014378A2 (pt) | 2020-05-19 |
US10328129B2 (en) | 2019-06-25 |
DK2790722T3 (en) | 2019-03-25 |
JP2015506920A (ja) | 2015-03-05 |
ES2713519T3 (es) | 2019-05-22 |
US20150010524A1 (en) | 2015-01-08 |
IL232999B (en) | 2019-03-31 |
AU2012352983A1 (en) | 2014-07-03 |
JP6202400B2 (ja) | 2017-09-27 |
WO2013089835A1 (en) | 2013-06-20 |
KR20140101857A (ko) | 2014-08-20 |
EP2790722B1 (en) | 2018-12-05 |
CA2858983C (en) | 2020-06-09 |
RU2642609C2 (ru) | 2018-01-25 |
IL232999A0 (en) | 2014-07-31 |
MX2014007103A (es) | 2015-05-11 |
CN104220087A (zh) | 2014-12-17 |
US20190314461A1 (en) | 2019-10-17 |
EP2790722A1 (en) | 2014-10-22 |
AU2012352983B2 (en) | 2017-09-21 |
US20170106057A1 (en) | 2017-04-20 |
KR101898438B1 (ko) | 2018-09-14 |
RU2014128564A (ru) | 2016-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX364495B (es) | Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos. | |
EP2760359A4 (en) | METHOD FOR TREATING EYE STATES | |
HK1189792A1 (zh) | 接合增強的植入物、系統和方法 | |
EP2753275A4 (en) | METHODS OF TREATING OCULAR CONDITIONS | |
EP2757887A4 (en) | PYRROLOPYRIDINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF HIV | |
ZA201400005B (en) | Method for treating eczema | |
ZA201208219B (en) | Method for treating wasterwater | |
BR112014004192A2 (pt) | composição de tratamento de sementes, e, método de tratamento de sementes | |
HK1215173A1 (zh) | 治療金黃色葡萄球菌相關疾病的方法 | |
EP2687705A4 (en) | MOTOR CONTROL DEVICE AND MOTOR CONTROL METHOD | |
EP2745793A4 (en) | TREATMENT SYSTEM AND CONTROL PROCEDURE FOR THE TREATMENT SYSTEM | |
EP2719349A4 (en) | TREATMENT SYSTEM, AND CONTROL METHOD FOR TREATMENT SYSTEM | |
BR112013022820A2 (pt) | método de tratamento | |
EP2775836B8 (en) | Methods for treating gout flares | |
PL2691219T3 (pl) | Sposób obróbki tekstyliów technicznych | |
IL229706A0 (en) | A method for treating the effects of a stroke | |
PL2717887T3 (pl) | Sposoby leczenia lub zapobiegania chorobie przeszczep przeciw gospodarzowi | |
EP2690536A4 (en) | INFORMATION PROCESSING DEVICE, ITS CONTROL METHOD, AND ASSOCIATED PROGRAM | |
HK1252353A1 (zh) | 治療精神分裂症的方法 | |
HRP20130367T1 (hr) | Postupak za preradu kože | |
EP2728701A4 (en) | EXCAVATOR, AND METHOD FOR CONTROLLING A SHOVELER | |
HK1209052A1 (en) | Method of treating scedosporium spp. infection | |
EP2709466A4 (en) | PROCESS FOR TREATING HONEY | |
ZA201407215B (en) | Method for emulsion treatment | |
GB201105523D0 (en) | Treatment method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |